Back to Journals » Clinical Ophthalmology » Volume 7

Topical rebamipide improves the ocular surface in mild lagophthalmos

Authors Itakura M, Itakura H, Kashima T, Akiyama H, Kishi S

Received 30 April 2013

Accepted for publication 10 June 2013

Published 1 July 2013 Volume 2013:7 Pages 1333—1338

DOI https://doi.org/10.2147/OPTH.S47445

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Mariko Itakura,1 Hirotaka Itakura,1,2 Tomoyuki Kashima,2 Hideo Akiyama,2 Shoji Kishi2

1Department of Ophthalmology, Maebashi Red Cross Hospital, Maebashi, Japan; 2Department of Ophthalmology, Gunma University, School of Medicine, Maebashi, Japan

Abstract: Administration of topical rebamipide improves the ocular surface in dry eye. We consecutively studied seven eyes in seven cases (three males and four females) with mild lagophthalmos (three cases after eyelid surgery, two cases of incomplete facial nerve palsy, and two cases of senile ectropion) during the treatment of corneal disorders with rebamipide eye drops four times daily for 2 weeks. The fluorescein corneal staining (FCS) score, tear film break-up time (TBUT), Schirmer's test, and decimal visual acuity were examined. Ocular symptoms were examined and scored by questioning each patient before and after administration of the drug. In all seven eyes, inferior corneal erosion decreased or disappeared within 2 weeks after administration of topical rebamipide. The FCS score was significantly improved (P < 0.05). The TBUT was significantly extended from 2.9 ± 0.5 seconds to 5.2 ± 0.4 seconds (P < 0.05). The scores of ocular symptoms, such as eye pain, dryness, blurred vision, and foreign body sensations, were significantly improved (P < 0.05).Topical rebamipide was effective for corneal disorders in mild lagophthalmos. This drug may provide a novel approach to treat lagophthalmos.

Keywords: dry eye, ectropion, eyelid surgery, facial nerve palsy, lagophthalmos, rebamipide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]